Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03218891
Other study ID # 2014/00345-0
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 1, 2016
Est. completion date February 1, 2022

Study information

Verified date March 2020
Source Hospital Israelita Albert Einstein
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and feasibility of cardiovascular rehabilitation in Patients with refractory angina, evaluate the effect of cardiovascular rehabilitation in patients with angina Refractory, by maximal oxygen consumption (VO2max) and global myocardial ischemic load by Stress Echocardiography; To evaluate the presence of myocardial injury, caused by physical stress, through ultra-sensitive troponin after sessions of aerobic physical activity, evaluating the behavior during the training period; To evaluate the effect of rehabilitation on the modulation of sympathetic activity and inflammation, muscular blood flow and lipid metabolism; To evaluate of the effect of rehabilitation on ventricular function through Stress echocardiography; Detection of ischemic episodes and arrhythmias identified during the Rehabilitation sessions through external cardiac monitoring (telemetry); Evaluate the quality of life assessment through the SF-36 questionnaire, Canadian Cardiovascular Society, the number of symptomatic episodes of ischemia, daily sublingual nitrate intake.


Description:

After signing the informed consent form, patients will be randomized into 4 groups: 1. Optimized clinical treatment group + physical training for 12 weeks (TF); 2. optimized clinical treatment group (CT); 3. Group with coronary insufficiency without angina (CD); Group 4: normal healthy subjects All patients will be submitted to the following procedures in 2 moments * (times 0 and 3): -Routine laboratory tests including study of total cholesterol, LDL-cholesterol, -HDL-cholesterol, including study of the functionality of HDL-c, triglycerides, complete blood count, renal function, fasting glycemia, glycosylated hemoglobin (HbA1C); - Dosage of biomarkers of myocardial ischemia (ultra-sensitive troponin); - Dosage of inflammatory markers: Tumor necrosis factor (TNFn), interleukins 1 and 6 (IL-1 and IL-6), ultra-sensitive C-reactive protein (CRP); - Vascular endothelial growth factor (VEGF) dosage; - ergospirometric test in cycloergometer; - Echocardiogram with physical stress with evaluation of myocardial perfusion and function; - Evaluation of sympathetic activity through microneurography; - Evaluation of vascular reactivity through ultrasound of the brachial artery. - Evaluation of muscular blood flow through plethysmography; - Isometric exercise protocols; - Mental stress protocol - Quality of Life Questionnaire; - Diary of angina. After the initial examinations, the candidates of the TF group will be evaluated by cardiovascular rehabilitation team, for training prescription, which will be performed in a hospital environment, supervised by a qualified doctor. The rehabilitation may be interrupted in any patient, for safety measure, if the investigator deems it appropriate. All patients in both groups will receive clinical follow-up during the protocol, with monthly consultations during the 12-week protocol period (time 0 to 3), in which clinical evaluations of symptoms and quality of life of the patients will be performed . Any clinical intercurrence will be promptly annotated and evaluated according to the need of the moment. After this period, routine outpatient follow-up is scheduled at the outpatient clinic, and counseling for unsupervised physical training, according to the results of the study. All laboratory, clinical, imaging, and functional parameters will be evaluated before and at the end of the protocol.


Recruitment information / eligibility

Status Completed
Enrollment 72
Est. completion date February 1, 2022
Est. primary completion date July 28, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 45 Years to 75 Years
Eligibility Group 1 and 2 Inclusion Criteria: - Stable angina functional class II to IV according to the classification of Canadian Cardiovascular Society (CCS) 39, or limiting angina in Perception of the patient; - Documented myocardial ischemia by imaging method; - Patients not eligible for myocardial revascularization procedures surgical conventional, due to the unfavorable anatomy; - Signature of the Free and Informed Consent Form. Exclusion Criteria: - Patients with definitive pacemaker or implantable cardioverter defibrillator (ICD); - Patients with non-sinus heart rhythm; - Patients with complete intraventricular block; - Acute coronary syndrome (myocardial infarction or unstable angina) or previous procedures for myocardial revascularization (angioplasty / surgery) less than 3 months; - Functional impossibility (orthopedic, rheumatic, neurological, or otherwise) or social for participation in the Rehabilitation Program; - Classification of risk for American Heart Association class D physical training (unstable ischemia, stenosis or severe or symptomatic valve insufficiency, congenital heart disease, decompensated heart failure, uncontrolled arrhythmias and other conditions that may be aggravated by exercise). Group 3 Inclusion Criteria: - Patients with coronary insufficiency without angina; - Signature of the Free and Informed Consent Form. Group 4 Inclusion Criteria: - Signature of the Free and Informed Consent Form; - Healthy; - Non-smokers; - Sedentary

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Cardiac Rehabilitation
The physical training program will start shortly after the initial exams have been completed. The physical training protocol will consist of a 12-week duration, with a frequency of 3 weekly sessions of 60 minutes duration each. The intensity will be prescribed from the echocardiogram with effort and cardiopulmonary test. All sessions will be monitored by telemetry and will be distributed as follows: 5 minutes warm up 30 to 40 minutes of aerobic exercise (treadmill). The training intensity will be prescribed individually, based on the results of the test results; 10 minutes of localized exercises; 5 minutes of relaxation.

Locations

Country Name City State
Brazil Instituto Israelita de Ensino e Pesquisa Albert Einstein 's (IIEP) São Paulo

Sponsors (3)

Lead Sponsor Collaborator
Hospital Israelita Albert Einstein Fundação de Amparo à Pesquisa do Estado de São Paulo, Instituto do Coracao

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cardiovascular rehabilitation in patients with refractory angina is safe; Evaluated number of patients who have any kind of cardiovascular event during rehabilitation, as well as number of sore throat during the sessions. 3 months of rehabilitation
Primary Cardiovascular rehabilitation in patients with refractory angina is efficient; Evaluated number of sore throat during the sessions. 3 months of rehabilitation
Primary Improve the maximal oxygen consumption Improvement of Maximal oxygen uptake (VO2max) 3 months of rehabilitation
Primary Improve the global myocardial ischemic load Reduction of myocardial ischemia, evidenced by improvement of the standard by effort echocardiography 3 months of rehabilitation
Secondary Reduction of myocardial injury caused by physical stress Improves levels of Troponin-T after 1 exercise session at the initial moment of the Protocol and after 3 months. 3 months of rehabilitation
Secondary Rehabilitation will modulate sympathetic activity Decreased sympathetic nerve activity measured by the amount of shots in his microneurography 3 months of rehabilitation
Secondary Improvement of ventricular function Improvement of ventricular function through stress echocardiography in patients undergoing rehabilitation 3 months of rehabilitation
Secondary Improvement of the quality of life Improvement of the quality of life measured through the SF-36 questionnaire. 3 months of rehabilitation
Secondary Rehabilitation will increase muscle blood flow Increase peripheral muscle blood flow measured by plethysmography. 3 months of rehabilitation
Secondary Reduction in the number of symptomatic episodes of ischemia Reduction in the number of episodes of ischemia, reduction of daily sublingual nitrate intake. 3 months of rehabilitation
Secondary Reduction of the daily consumption of sublingual nitrate Reduction of daily sublingual nitrate intake. 3 months of rehabilitation
Secondary Improve the functional class of Refractory Angina Improve the functional class decrease of angina (according to Canadian Cardiovascular Society classification) 3 months of rehabilitation
See also
  Status Clinical Trial Phase
Completed NCT01205893 - Coronary Sinus Reducer for Treatment of Refractory Angina - COSIRA Phase 2
Not yet recruiting NCT05711849 - Assessing the Safety and Effectiveness of Intracoronary Stem Cells in Patients With Refractory Angina Phase 2
Suspended NCT04306237 - A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina Phase 2
Recruiting NCT04892537 - Coronary Sinus Reducer Objective Impact on Symptoms, MRI Ischaemia and Microvascular Resistance N/A
Completed NCT00694642 - Safety and Efficacy of Autologous Endothelial Progenitor Cell CD 133 for Therapeutic Angiogenesis Phase 1/Phase 2
Suspended NCT00820586 - Intramyocardial Delivery of Autologous Bone Marrow Phase 2
Recruiting NCT04368819 - Allopurinol in Patients With Refractory Angina to Improve Ischemic Symptoms Phase 2/Phase 3
Recruiting NCT03455725 - CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial N/A
Completed NCT01966042 - Study Protocol of Intramyocardial Injection of Autologous Bone Marrow Stem Cells for Refractory Angina Phase 2
Recruiting NCT03991871 - HARapan kiTa ECP (External Counter Pulsation) Study HARTEC Study N/A
Recruiting NCT05102019 - Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II N/A
Completed NCT01796912 - Lipoprotein Apheresis in Refractory Angina Study N/A
Completed NCT03350737 - Coronary Arteriogenetic Heparinized Exercise N/A
Recruiting NCT01566175 - Use of the Neovasc Coronary Sinus Reducer System for the Treatment of Refractory Angina Pectoris in Patients With Ngina Class 3-4 Who Are Not Candidates for Revascularization N/A
Recruiting NCT05492110 - Coronary Sinus Reducer Implantation in Patients With Ischaemia and Non-obstructed Coronary Arteries and Coronary Microvascular Dysfunction. N/A
Recruiting NCT04606459 - COSIMA: COronary SInus Reducer for the Treatment of Refractory Microvascular Angina N/A